Menu
Recruiting NCT04115566

Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

Observational Hidradenitis Suppurativa

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Hidradenitis Suppurativa. Basic parameters: from 10 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.

Primary outcome measures

  • Primary Objective [Time frame: 2019-2035]
Secondary outcome measures (1)
  • Secondary Objective [Time frame: 2019-2035]

Eligibility criteria

Inclusion criteria

  • Male or female ≥ 10 years of age
  • Diagnosis of HS by a dermatologist or practitioner experienced in making a diagnosis of HS
  • Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

Exclusion criteria

1\. Inability to give informed consent or unavailability of a parent/guardian who is able and willing to give informed consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • University of California San Francisco — San Francisco

Identifiers

NCT: NCT04115566 · 18-27002

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗